RANK448. The biopharmaceutical company makes its debut on the Fortune 500 this year, riding the wave of a 49% year-over-year...
vrtx stock
Out of 13 analysts, 5 (38.46%) are recommending VRTX as a Strong Buy, 2 (15.38%) are recommending VRTX as a...
RANK448. The biopharmaceutical company makes its debut on the Fortune 500 this year, riding the wave of a 49% year-over-year...